Selecta Biosciences (NASDAQ:SELB) reported quarterly sales of $19.66 million which beat the analyst consensus estimate of $6.24 million by 215.11 percent.
Wedbush Maintains Outperform on Turtle Beach, Lowers Price Target to $12
Wedbush analyst Michael Pachter maintains Turtle Beach (NASDAQ:HEAR) with a Outperform and lowers the price target from $22 to $12.